Literature DB >> 18407433

Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.

Carlo Capirci1, Vincenzo Valentini, Luca Cionini, Antonino De Paoli, Claus Rodel, Robert Glynne-Jones, Claudio Coco, Mario Romano, Giovanna Mantello, Silvia Palazzi, Falchetti Osti Mattia, Maria Luisa Friso, Domenico Genovesi, Cristiana Vidali, Maria Antonietta Gambacorta, Alberto Buffoli, Marco Lupattelli, Maria Silvia Favretto, Giuseppe La Torre.   

Abstract

PURPOSE: In the literature, a favorable prognosis was observed for complete pathologic response after preoperative therapy (ypCR) in patients with locally advanced rectal cancer. The aim of this study is to verify whether ypCR predicts a favorable outcome in a large series of patients. METHODS AND MATERIALS: The Gastro-Intestinal Working Group of the Italian Association of Radiation Oncology collected clinical data for 566 patients with ypCR (ypT0N0) after neoadjuvant therapy. Eligibility criteria included locally advanced rectal cancer with no evidence of metastases at the time of diagnosis, evidence of ypCR after preoperative radiotherapy +/- chemotherapy (CT).
RESULTS: Median radiation dose was 50 Gy. A total of 527 patients (93%) received one of 12 different neoadjuvant CT schedules. Sphincter preservation, anteroposterior resection, and endoscopic surgery were performed in 73%, 22%, and 5% of patients, respectively. Adjuvant CT was administered to 22% of patients. Median follow-up was 46.4 months. Locoregional recurrence occurred in 7 patients (1.6%). Distant metastases occurred in 49 patients (8.9%). Overall, 5-year rates of disease-free survival, overall survival, and cancer-specific survival were 85%, 90%, and 94%, respectively. In multivariate analysis, only age and clinical stage statistically correlated with survival outcome. Adjuvant CT was still of borderline significance (worse for adjuvant CT). No relation was found between survival and neoadjuvant CT schedules.
CONCLUSION: A ypCR after neoadjuvant therapy identified a favorable group of patients, even in this large series of 566 patients collected in 61 centers. Locoregional recurrence occurred only in 1.6% patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18407433     DOI: 10.1016/j.ijrobp.2007.12.019

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  135 in total

Review 1.  Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer.

Authors:  Takashi Akiyoshi; Takashi Kobunai; Toshiaki Watanabe
Journal:  Surg Today       Date:  2012-06-16       Impact factor: 2.549

2.  Long-term results with oral fluoropyrimidines and oxaliplatin-based preoperative chemoradiotherapy in patients with resectable rectal cancer. A single-institution experience.

Authors:  Robert Díaz Beveridge; Jorge Aparicio; Alejandro Tormo; Rafael Estevan; Josefina Artes; Alejandra Giménez; Ángel Segura; Susana Roldán; Rosana Palasí; David Ramos
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

3.  Partial pathologic response and nodal status as most significant prognostic factors for advanced rectal cancer treated with preoperative chemoradiotherapy.

Authors:  Marianne Huebner; Bruce G Wolff; Thomas C Smyrk; Jeremiah Aakre; David W Larson
Journal:  World J Surg       Date:  2012-03       Impact factor: 3.352

4.  Treatment Intensification for Locally Advanced Rectal Cancer: Impact on Pathological Complete Response and Outcomes.

Authors:  Monica DI Tommaso; Consuelo Rosa; Luciana Caravatta; Antonietta Augurio; Valentina Borzillo; Sara DI Santo; Francesca Perrotti; Maria Taraborrelli; Roberta Cianci; Paolo Innocenti; Pierluigi DI Sebastiano; Antonella Colasante; Domenico Angelucci; Massimo Basti; Giulia Sindici; Lorenzo Mazzola; Giuseppe Pizzicannella; Nicola DI Bartolomeo; Michele Marchioni; Marta DI Nicola; Domenico Genovesi
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

5.  Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.

Authors:  Alissa Greenbaum; David R Martin; Thèrése Bocklage; Ji-Hyun Lee; Scott A Ness; Ashwani Rajput
Journal:  Clin Colorectal Cancer       Date:  2019-02-13       Impact factor: 4.481

6.  Time to Redefine the Role of Routine Combined-Modality Therapy for Invasive Stage-II/III Rectal Cancer?

Authors:  Lily L Lai; Charles R Thomas
Journal:  Gastrointest Cancer Res       Date:  2009-03

Review 7.  Current issues in locally advanced colorectal cancer treated by preoperative chemoradiotherapy.

Authors:  In Ja Park; Chang Sik Yu
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

Review 8.  Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy.

Authors:  Valerie M Nelson; Al B Benson
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

9.  Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer.

Authors:  Byoung Yong Shim; Ji-Han Jung; Kang-Moon Lee; Hyung-Jin Kim; Sook Hee Hong; Sung Hwan Kim; Der Sheng Sun; Hyeon-Min Cho
Journal:  Int J Colorectal Dis       Date:  2012-07-31       Impact factor: 2.571

10.  Pathologic response to neoadjuvant treatment in locally advanced rectal cancer and impact on outcome.

Authors:  Mahshid Jalilian; Sidney Davis; Mohammadreza Mohebbi; Bhuvana Sugamaran; Ian W Porter; Stephen Bell; Satish K Warrier; Roger Wale
Journal:  J Gastrointest Oncol       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.